Ranbaxy Mohali Plant's U.S. Acceptance May Have Hung By A Hair
This article was originally published in PharmAsia News
The U.S. FDA's ban on drugs imported from the Mohali, India, production plant of Ranbaxy Laboratories appears to have been based in part on detection of a possible arm hair embedded in a single tablet.
You may also be interested in...
The Phase III FIDELIO trial of finerenone has been a success but analysts want to see some actual data before declaring it an unqualified one.
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.